Premium
Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials
Author(s) -
Mo Allison,
McQuilten Zoe K.,
Wood Erica M.,
Weinkove Robert
Publication year - 2017
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13434
Subject(s) - medicine , myelodysplastic syndromes , clinical trial , intensive care medicine , blood transfusion , disease , red blood cell transfusion , pediatrics , anemia , bone marrow
Optimal red cell transfusion thresholds in myelodysplastic syndrome are not established. In this survey of 110 Australasian haematologists’ practice in myelodysplastic syndrome‐related anaemia, 92% of respondents set transfusion thresholds, and would typically transfuse at a haemoglobin <80 g/L aiming for a post‐transfusion haemoglobin 90–100 g/L, reflecting a restrictive transfusion strategy. Higher thresholds were typically used for patients with cardiovascular disease or anaemia symptoms. These results will inform the design of clinical trials comparing transfusion thresholds.